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a b s t r a c t
The steroid receptor coactivator p/CIP, also known as SRC-3, is an oncogene commonly ampliﬁed in breast and
ovarian cancers. p/CIP is known to associate with coactivator arginine methyltransferase 1 (CARM1) on select
estrogen responsive genes. We have shown, using a ChIP-on-chip approach, that in response to stimulation
with 17β-estradiol (E2), the p/CIP/CARM1 complex is recruited to 204 proximal promoters in MCF-7 cells.
Many of the complex target genes have been previously implicated in signaling pathways related to oncogenesis.
Jak2, a member of the Jak/Stat signaling cascade, is one of the direct E2-dependent targets of the p/CIP/CARM1
complex. Following E2-treatment, histone modiﬁcations at the Jak2 promoter are reﬂective of a transcriptionally
permissive gene, and modest changes in RNA and protein expression lead us to suggest that an additional
factor(s) may be required for a more notable transcriptional and functional response. Bioinformatic examination
of the 204 proximal promoter sequences of p/CIP/CARM1 targets supports the idea that transcription factor
crosstalk is likely the favored mechanism of E2-dependent p/CIP/CARM1 complex recruitment. This data may
have implications towards understanding the oncogenic role of p/CIP in breast cancer and ultimately allow for
the identiﬁcation of new prognostic indicators and/or viable therapeutic targets.
Crown Copyright © 2013 Published by Elsevier B.V. All rights reserved.

1. Introduction
Transcriptional activation is a highly dynamic process that involves a
large and diverse class of proteins known as coactivators. Coactivators
mediate speciﬁc transcriptional responses by utilizing several interrelated mechanisms involving chromatin remodeling and covalent
modiﬁcation of histones. These mechanisms often work cooperatively
to alter the structural restrictions imposed by packaging DNA into chromatin. Additionally, many coactivators function as adaptors/bridging
factors to recruit additional coactivator proteins to target genes [1].
Detailed genome-wide chromatin immunoprecipitation (ChIP) studies
of binding sites for various transcription factors, such as the estrogen
receptor (ER), have provided signiﬁcant insight into the dynamics
of coregulator activity at selected targets [2]. For example, the ER
undergoes a cyclic pattern of association and dissociation at selected
ER targets [2,12], and its association with DNA often coincides with
the recruitment of several ERα-interacting complexes. These complexes
consist of various combinations of coregulators, the basal transcriptional
machinery, as well as RNA polymerase II [3]. The p/300 CBP interacting
protein (p/CIP), also known as SRC3/AIB1/ACTR/RAC3, [4–9] belongs to
⁎ Corresponding author at: Cancer Research Laboratories, London Regional Cancer
Program, London, Ontario, Canada N6A 4L6. Tel.: +1 519 685 8692; fax: + 1 519 685
8646.
E-mail address: jtorchia@uwo.ca (J. Torchia).

a family of steroid receptor coactivator (SRC) proteins containing two
additional family members (SRC1 and SRC2). p/CIP interacts directly
with the liganded ER, and functions primarily as a bridging factor that
binds to hormone-bound nuclear receptors to promote coactivator complex assembly [10,11]. ChIP assays have established that p/CIP associates
with many endogenous ER target genes in response to 17β-estradiol
(E2), including pS2 [3], cathepsin D [12] and cyclin D1 [13]. Additionally,
p/CIP interacts with other liganded nuclear receptors [5,7–9] and other
classes of transcription factors such as E2F [14] and NFkB [15].
Several studies have shown that p/CIP undergoes a variety of posttranslational modiﬁcations in response to extracellular signals such
as phosphorylation, acetylation, methylation, ubiquitination, and
sumoylation [10,16–20]. These modiﬁcations provide an important
regulatory mechanism that deﬁnes the combinatorial associations
with additional coactivators, resulting in the formation of diverse
multimeric complexes which generate distinct gene expression programs. The coactivator-associated arginine methyltransferase protein
(CARM1) is one such coactivating partner that interacts with the carboxy
terminus of p/CIP as well as other SRC proteins. CARM1 has been shown
to methylate proteins involved in RNA processing as well as speciﬁc
arginines at positions 17 and 26 on histone H3, suggesting that CARM1
plays a direct role in gene transcription [21,22]. Furthermore, several
studies have demonstrated a correlation between recruitment of
CARM1, methylation of histone H3, and activation of several steroidresponsive genes [23–26]. Sequential ChIP analysis has identiﬁed a
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complex consisting of p/CIP and CARM1 on several estrogen responsive
genes [16,27,28], and CARM1 synergizes with p/CIP to activate NRdependent transcription [29–31]. Collectively, these studies suggest
that direct recruitment of CARM1 by p/CIP represents an essential
activating step for ER-dependent transcription. In the present study,
we have used sequential ChIP–reChIP assays in conjunction with
genome-wide microarray screening to identify E2-dependent genepromoter targets of the p/CIP/CARM1 complex. Importantly, our studies
identify the JAK2 promoter as a novel target for the p/CIP/CARM1 complex in response to E2, indicating a novel interplay between ER signaling
and the JAK/STAT pathway at the level of transcription, which may have
implications in ER positive breast cancers where the JAK/STAT signaling
pathway is constitutively active.

the studies conducted by both the comparison groups encompassed
binding sites throughout the entire genome. Notably, in each of studies
used for comparative analysis, only a small proportion (4–7%) of ERinteraction sites were located within promoter regions. Nevertheless,
our analysis indicated that 65/204 (32%) [33] and 118/204 (58%) [34]
(Fig. 3a) of identiﬁed p/CIP/CARM1 complex targets have previously
been shown to display ER binding following E2 treatment. Moreover,
59/204 (29%) p/CIP/CARM1 complex targets were ER binding targets
common to both studies, and were therefore considered to be high conﬁdence ER interactors (Fig. 3b, Table 1).

2. Results

Since our p/CIP/CARM1 target genes may include genes directly
and/or indirectly regulated by the ER, we examined 1 kb upstream
promoter sequences of the gene targets for transcription factor binding
site enrichment, to discern potential mechanisms for E2-dependent
p/CIP/CARM1 binding. Using a candidate scanning approach, we
conducted a search for enriched motifs within our target gene promoter
sequences. Previous studies have shown that in addition to directly
binding ER-binding elements (EREs) in response to ligand, the ER associates with C/EBP [35], and can also be targeted to the DNA via interaction with Oct [36,37], Sp1 [38,39] and/or AP-1 [40,41]. Forkhead motifs
were also of interest, as evidence has linked the presence of the FoxA1/
HNF3α motif to ER recruitment [33,42]. When p/CIP/CARM1 target
gene promoter sequences were compared to a background control set
of human housekeeping gene promoters, many enriched putative binding motifs were identiﬁed (Table A2). While EREs were shown as being
signiﬁcantly enriched among p/CIP/CARM1 complex promoters, it was
not the most prevalent motif when ranked either by p-value or by
enrichment score. Sp1, C/EBP, Oct, FoxA1, and AP-1 motifs were all
found to be more signiﬁcantly enriched than EREs among the p/CIP/
CARM1 target gene promoters we identiﬁed. Evaluation of these consensus sites within the individual promoter sequences conﬁrmed the
presence and relative abundance of the motifs, with approximately
12% of target promoters containing one or more EREs, 31% C/EBPα motifs, 24% Sp1, 20% Oct, 10% FoxA1, and 9% contain putative AP-1 sites
(Fig. 3c). Several of the promoters contain consensus sites for more
than one of the considered transcription factors. EREs occurred simultaneously more often with C/EBP, Oct, and Sp1 motifs rather than with
FoxA1 or AP-1 motifs (Fig. A1). While a negative correlation between
ERE and AP-1 elements has previously been observed [33], our ﬁndings
are contrary to previous reports [33,42] in that FoxA1 motifs did not consistently coincide with the presence of EREs. This discordance is likely
due to our exclusive focus on the proximal promoter, since Kwon et al.
also noted limited association of FoxA1 sites with proximal promoter
ER binding events as identiﬁed by ChIP-DSL [43]. The overall enrichment
pattern of putative transcription factor motifs did not change for the 59
p/CIP/CARM1 target genes that are considered to be high conﬁdence ER
binding targets (Fig. A2a) or for targets transcriptionally upregulated
following E2 treatment (Fig. A2b).
Collectively, this analysis demonstrates a consistent pattern of
enriched motifs among p/CIP/CARM1 complex target promoters,
and suggests that transcription factor crosstalk is likely the favored
mechanism of E2-dependent p/CIP/CARM1 recruitment at the proximal
promoters of target genes, regardless of ER binding status or transcriptional state. The presence of EREs suggests that the classical response
with direct binding of the ER is also involved, albeit to a lesser extent.

2.1. Identiﬁcation of genes directly targeted by the p/CIP/CARM1 complex
in response to β-estradiol (E2)
To identify p/CIP/CARM1 target genes which play a role in E2dependent signaling we embarked on a genome-wide chromatin
immunoprecipitation assay approach based on DNA Selection and
Ligation (ChIP-DSL) [32]. Brieﬂy, MCF-7 cells were treated with E2
for 45 min and a standard ChIP assay was performed using an antibody
against p/CIP. The immunoprecipitated material was then reChIPed
using a CARM1-speciﬁc antibody. The resulting p/CIP/CARM1-enriched
and input DNA was then puriﬁed, biotinylated, and combined with
20,000 unique predesigned oligonucleotides. After annealing, the
biotinylated DNA was selected using streptavidin Sepharose and
hybridized to a 20,000 gene promoter array (Fig. 1a). The identiﬁcation
of E2-dependent p/CIP/CARM1 targets was based on the following
criteria: ﬁrst, we established a list of genes displaying a statistically
signiﬁcant enrichment relative to input (pb 0.05) regardless of the
treatment. From this list, genes that displayed a 2-fold or greater enrichment in the E2-treated cells relative to control were identiﬁed (i.e. a
twofold or greater enrichment was observed in cells treated with E2
as compared to the untreated cells). The experiment was performed
in triplicate and based on these criteria we identiﬁed 204 gene
promoters that become co-occupied by p/CIP and CARM1 in response
to E2 treatment for 45 min (Fig. 1b–c & Table A1). To validate the
ChIP-DSL analysis, we performed independent ChIP–reChIP experiments
for a random set of target genes identiﬁed (Fig. 2). In the majority of
cases tested, treatment with E2 resulted in the simultaneous recruitment of p/CIP and CARM1, indicating that the false positive rate was
extremely low. It should be emphasized that in our experimental
protocol we have identiﬁed gene targets for p/CIP/CARM1 as a consequence of E2 treatment; which may include genes directly regulated
by the ER, as well as genes indirectly regulated by the ER through its
association with other transcription factors, or via a nongenomic
pathway.
2.2. The ER interacts with a fraction of p/CIP/CARM1 target gene promoters
To better validate our analysis, we compared our results with two
previous studies examining direct E2-dependent ER binding on a
genome-wide scale [33,34]. Carroll et al. discerned 3665 unique E2dependent ER binding sites using a ChIP–chip Affymetrix Human
tiling array approach [33], while Welboren et al. used a ChIP-Seq
approach to identify 10,205 genome-wide ER-interaction sites [34].
Using the published chromosomal locations for ER-binding targets
identiﬁed in these studies, we distinguished known genes present
within and/or adjacent to these genomic sites. Next, we conducted direct
gene-by-gene comparisons of p/CIP/CARM1 targets in our study with
the ER targets identiﬁed in each of the previous studies. An important
consideration for the purposes of this comparison is that while our
analysis was restricted to the 1 kb proximal promoter regions of genes,

2.3. Binding site enrichment in the promoters of p/CIP/CARM target gene
promoters

2.4. A proportion or p/CIP/CARM1 target genes are directly regulated by E2
To correlate p/CIP/CARM1 binding data with the E2-dependent
transcriptional response, we performed gene expression proﬁling
using MCF-7 cells treated with 10 nM E2 for 12 h. RNA was isolated,
reverse transcribed and hybridized to Affymetrix microarrays. A list
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Fig. 1. ChIP-DSL analysis of p/CIP/CARM1 target genes in MCF-7 cells. (A) Sequential ChIP–reChIP coupled to DNA Selection and Ligation (ChIP-DSL) was used to assess global
promoter occupancy by the p/CIP/CARM1 complex. Sequential ChIP–reChIP was performed using either IgG or anti-p/CIP followed by anti-CARM1 antibodies in control and
17β-estradiol stimulated MCF-7 cells. Total input and antibody-enriched DNA were biotinylated and annealed to a 40mer oligonucleotide pool. Annealed oligonucleotides were
selected for with streptavidin-coated metal beads, and appropriate 40mers were ligated to form an 80mer, then labeled and hybridized to the Hu20K array, containing
sequences from 20,000 unique human promoters. Scatter plots of (B) control and (C) 17β-estradiol stimulated p/CIP/CARM1 ChIP (y axis) versus input (x axis) from three
independent biological replicates, demonstrating a normal cluster distribution. (D) Venn diagram depicting the overlap in genes enriched from three independent ChIP-DSL experiments
(Rep 1 to 3).

of differentially expressed genes from three independent experiments
was generated (p-value b 0.05 was used as the cutoff). Based on this
criteria, we identiﬁed 396 and 231 genes that were signiﬁcantly
upregulated or downregulated, respectively, following E2-treatment
(Fig. 4a), consistent with previous expression proﬁling studies [43,44].
Comparison of the microarray expression data with the ChIP-DSL
results determined that 33 (16.2%) targets proximally bound by the
p/CIP/CARM1 complex are signiﬁcantly upregulated, and 8 (3.9%)
p/CIP/CARM1 target genes were downregulated following E2 treatment
(Table 2). The reliability of this analysis was conﬁrmed by quantitative
real-time PCR (qPCR) analysis of selected genes (Fig. 4b). These ﬁndings
suggests that proximal binding may be more relevant for transcriptionally
upregulated genes, and shows that while the p/CIP/CARM1 complex may

have a preferential role in transcriptional activation, it also plays a direct
role in the repression of speciﬁc genes.
2.5. The JAK/STAT signaling pathway is a central target for p/CIP/CARM1
Using Ingenuity Pathway Analysis we were also able to identify a
number of networks consisting of target genes that are functionally
or biochemically linked. Several of the genes play a role in disease
(Fig. 5a), and the molecular and cellular functions most associated
with p/CIP/CARM1 target genes have been linked to the initiation
and progression of cancer (Fig. 5b). We found that the network
containing one of the highest number of functionally linked targets
is the canonical JAK/STAT signaling pathway. Several interconnected
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Fig. 2. ChIP analysis of selected direct p/CIP/CARM1 target genes. Control and 17β-estradiol stimulated MCF-7 cells were cross-linked with 1% formaldehyde, and sequential ChIP–reChIP
was performed using either IgG or anti-p/CIP followed by anti-CARM1. Recovered DNA was assayed by PCR using primers corresponding to the promoter regions indicated. Selected target
genes shown are pS2, Ccna2, Nfkb1, Dyrk1a, Wbp11, Il15ra, Tgfb1, Nek4, Kras2, and Mapk4.

genes within this pathway are direct targets for p/CIP and CARM1,
including janus tyrosine kinase 2 (Jak2), the interleukin 15 receptor
(Il15ra), and Pias2-a sumo ligase, which functions as a coregulator
for STAT proteins (Fig. 4c, colored targets). Adding to the implied
relevance of p/CIP/CARM1-mediated regulation of this pathway, Stat3
and Stat5 (Fig. 4c, gray targets) were also identiﬁed as E2-dependent
p/CIP/CARM1 binding targets, however, they were not included on the
ﬁnal list as they did not meet the applied statistical criteria. We focused
our initial analysis on the Jak2 gene. JAK2 plays a central role in JAK/
STAT signaling and mammary gland development, and hyperactivation
of this protein is associated with cancer initiation. Importantly, functional ablation of JAK2 in mice protects against the onset of mammary
tumorigenesis [45].

2.6. E2-dependent regulation of JAK2
JAK2 expression was assessed using qPCR following E2 treatment of
MCF-7 cells for various time periods. We observed an initial decrease in
Jak2 expression 1 h following E2 treatment, and a gradual increase in
expression thereafter, such that at 12 and 24 h the expression levels
are consistent with preliminary expression array data, with an approximately 1.5-fold increase in expression when compared to the untreated
control (pb 0.05) (Fig. 4b). Analysis of JAK2 protein levels exhibit a
corresponding trend, with a modest increase (~1.3 fold) in protein
expression after 12 and 24 h of E2 stimulation, followed by a decrease
to control unstimulated expression levels at 72 h (Fig. 4d).
To validate recruitment of p/CIP and CARM1 to speciﬁc regions of
the Jak2 promoter we performed ChIP assays. For the purposes of this
analysis, we used a region of the promoter that corresponds to a region
787 to 950 bp upstream of the transcriptional start site (TSS) (Fig. 6a).
An ERE-Sp1 half-site was identiﬁed within this portion of the Jak2
promoter.

Cells were treated with E2 for 45 min and promoter occupancy was
assessed by sequential ChIP assay using speciﬁc antibodies recognizing
p/CIP and CARM1. In addition, ChIP assays were performed using an
antibody against the ER to assess a possible mechanism of recruitment
for the p/CIP/CARM1 complex to the Jak2 promoter. We found that
the p/CIP/CARM1 complex binds in a ligand-dependent manner to the
Jak2 promoter (Fig. 6b). Importantly, we also determined that the ER
also binds Jak2 in response to ligand (Fig. 6b). The presence of both
the p/CIP/CARM1 complex and the ER at the same region of the promoter
suggests that E2-dependent complex recruitment to the Jak2 promoter is
mediated through its interaction with the ERE-associated ER. This
ﬁnding is consistent with the putative status of Jak2 as one of the
59 high-conﬁdence ER targets.
To determine whether the E2-dependent assembly of a p/CIP/CARM1
complex impacts the chromatin marks at the Jak2 promoter, ChIP
analysis was performed using antibodies corresponding to histone
modiﬁcations associated with transcriptional status; histone H3 lysine
4 trimethylation (H3K4me3) and acetylation of histone H3 at Lysines 9
and 14 (H3Ac) are modiﬁcations generally indicative of transcriptionally
active chromatin structure [46,47]. In addition, CARM1 is known to
asymmetrically dimethylate arginine 17 on histone H3 (H3R17me2), a
mark that is also associated with transcriptional activation [48].
E2-dependent changes in histone modiﬁcations were observed at
the Jak2 promoter. In response to treatment, there was a modest
increase in acetylation of H3K9 and H3K14 (H3K9/14ac) (Fig. 6c) and
a statistically signiﬁcant enrichment in dimethylation of H3R17me
(Fig. 6d), consistent with recruitment of a functional p/CIP/CARM1
complex. Surprisingly, trimethylation of H3K4 remained unchanged
by E2 treatment (Fig. 6c), perhaps suggestive of a transcriptionally permissive but not fully active gene state, in agreement with modest
E2-dependent increases in mRNA observed (Fig. 4b).
To determine if the changes in histone modiﬁcations are dependent
on the presence of p/CIP, quantitative ChIP analysis was performed on
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Fig. 3. Binding site enrichment analysis of p/CIP/CARM1 target promoter sequences. (A) Pie charts indicating the proportion of p/CIP/CARM1 target genes that are known to bind the
ER based on comparison with ChIP–chip analysis performed by Carroll et al. (top) and ChIP-Seq analysis performed by Welboren et al. (bottom). (B) Venn diagram showing overlap
of p/CIP/CARM1 direct target genes (highlighted in blue) with ER-binding sites identiﬁed by ChIP–chip reported by Caroll et al. and identiﬁed by ChIP-Seq reported by Welboren et
al. 59 p/CIP/CARM1 target genes were common to both the Carroll et al. and Welboren et al. analysis, and were considered to be high conﬁdence ER-binding targets. (C) Bar graph
showing the number of individual p/CIP/CARM1 target promoters that contain ERE, Sp1, AP-1, FoxA1, C/EBP, and Oct binding motifs.

the Jak2 promoter following siRNA-mediated gene silencing of p/CIP.
p/CIP was present minimally on the promoter despite p/CIP depletion
(Fig. 7b), likely due to incomplete knockdown (Fig. 7a). The level of
p/CIP present on the promoter was increased in response to hormone
(Fig. 7b). The functional effect of p/CIP depletion was determined by
ChIP assay evaluating the presence of the CARM1-dependent histone
modiﬁcation H3R17me2 in response to E2. As a chromatin mark associated with transcriptional activation, in the absence of p/CIP [and
complex] recruitment, E2-dependent dimethylation of R17 on histone
H3 was reduced (Fig. 7b), indicating that p/CIP is likely required for
recruitment of CARM1, and its subsequent methyltransferase activity.
To further our understanding of the role that the p/CIP/CARM1
complex plays in regulating Jak2, we assessed its E2-dependent expression in the absence of p/CIP or CARM1. When a control siRNA was
used, we saw a statistically signiﬁcant induction of Jak2 expression,
based on realtime PCR, after 12 and 24 h of E2 treatment. However,
when p/CIP was downregulated using siRNA, this effect was diminished
(Fig. 7c). A similar experiment was performed following CARM1 knockdown and, although the knockdown was not complete, there was a

more dramatic loss of E2-dependent Jak2 expression as compared to
p/CIP knockdown (Fig. 7d). Interestingly, when MCF7 cells were treated
with E2, we also observed an increase in Stat3 phosphorylation,
indicative of E2-dependent JAK/STAT pathway activation. However,
when either p/CIP or CARM1 was depleted, this effect was lost
(Fig. 7c–d). Collectively, this data suggests that p/CIP and CARM1 are
in part required for the E2-dependent regulation of Jak2 transcription
and activation of the JAK/STAT signaling pathway in MCF7 cells.
3. Discussion
In the present study, we identiﬁed E2-dependent target genes for
the p/CIP/CARM1 coregulatory complex. We then determined the
transcriptional status of those genes following 12 h E2 treatment,
and compared the lists with known ER binding sites in an attempt to
clarify a mechanism for complex recruitment and subsequent gene
regulation.
Global characterization of p/CIP (SRC-3) binding sites conducted by
Lanz et al. identiﬁed 12,294 E2-dependent targets using ChIP-Seq, 5512
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Table 1
p/CIP/CARM1 target genes bind the ER.
Gene ID

Accession number

Description

TLR3
DBC1
LAP3
CLDN12
SLC4A5
PTER
TRAF3
LETM1
IGSF4/CADM1
OCA2
SLC26A1
FRMD1
N4BP1
CTNND1
CDH7
RAD9B
ECT2
PCSK5
GATM
TUBGCP6
KCTD16
TGFB1
NEK4
RPS4X
STARD4
HRASLS
PKP4
SMARCAL1
CD9
C9orf95
TMEM16F
IVNS1ABP
DDX54
ITPKB
POLR2F
LAMA1
TSHB
RDH10
KCNQ1
KCTD3
PCP4
LRFN4
ABAT
PTPRJ
JAK2
GPR132
HARS
MDS009
POLG
HSD17B12
AKAP13
DPYS
DYRK1A
EDC3
SLC39A10
SAMD3
FLRT2
MGC14156
MXD3

NM_003265
NM_014618
NM_015907
NM_012129
NM_021196
NM_030664
NM_003300
NM_012318
NM_014333
NM_000275
NM_022042
NM_024919
NM_153029
NM_001331
NM_033646
NM_152442
NM_018098
NM_006200
NM_001482
NM_020461
XM_098368
NM_000660
NM_003157
NM_001007
NM_139164
NM_020386
NM_003628
NM_014140
NM_001769
NM_017881
XM_113743
NM_006469
NM_024072
NM_002221
NM_021974
NM_005559
NM_000549
NM_172037
NM_000218
NM_016121
NM_006198
NM_024036
NM_000663
NM_002843
NM_004972
NM_013345
NM_002109
NM_020234
NM_002693
NM_016142
NM_006738
NM_001385
NM_101395
NM_025083
XM_047707
NM_152552
NM_013231
NM_032906
NM_031300

Transmembrane receptor
Peptidase
Peptidase
Calcium-independent cell–cell adhesion
Solute carrier family 4, sodium bicarbonate cotransporter, member 5
Phosphotriesterase related
TNF receptor-associated factor 3/apoptosis
Leucine zipper-EF-hand containing transmembrane protein 1
Cell adhesion molecule 1/tumor suppressor
Oculocutaneous albinism II
Solute carrier family 26 (sulfate transporter), member 1
FERM domain containing 1
NEDD4 binding protein 1
Catenin (cadherin-associated protein), delta 1
Cadherin 7, type 2
RAD9 homolog B (S. cerevisiae)/DNA replication
Epithelial cell transforming sequence 2 oncogene
Proprotein convertase subtilisin/kexin type 5
Glycine amidinotransferase (L-arginine:glycine amidinotransferase)
Tubulin, gamma complex associated protein 6
Potassium channel tetramerization domain containing 16
Growth factor
Enzyme
Ribosomal protein S4, X-linked
StAR-related lipid transfer (START) domain containing 4
HRAS-like suppressor
Plakophilin 4/cell adhesion
SWI/SNF related, matrix associated, regulator of chromatin, a-like 1
CD9 molecule/cell adhesion
Orf
Transmembrane protein 16 F
Inﬂuenza virus NS1A binding protein
DEAD (Asp-Glu-Ala-Asp) box polypeptide 54/transcriptional regulator
Inositol 1,4,5-trisphosphate 3-kinase B
Polymerase (RNA) II (DNA directed) polypeptide F
Laminin, alpha 1/cell adhesion protein
Thyroid stimulating hormone, beta
Retinol dehydrogenase 10 (all-trans)
Potassium voltage-gated channel, KQT-like subfamily, member 1
Potassium channel tetramerization domain containing 3
Purkinje cell protein 4
Leucine rich repeat and ﬁbronectin type III domain containing 4
4-aminobutyrate aminotransferase
Protein tyrosine phosphatase, receptor type, J
Janus kinase 2 (a protein tyrosine kinase)
G protein-coupled receptor 132
Histidyl-tRNA synthetase
DTWD1 DTW domain containing 1
Polymerase (DNA directed), gamma
Hydroxysteroid (17-beta) dehydrogenase 12
A kinase (PRKA) anchor protein 13
Dihydropyrimidinase
Dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated kinase 1A
Homo sapiens enhancer of mRNA decapping 3 homolog (S. cerevisiae)
Solute carrier family 39 (zinc transporter), member 10
Sterile alpha motif domain containing 3
Fibronectin leucine rich transmembrane protein 2/cell adhesion
PIGY phosphatidylinositol glycan anchor biosynthesis, class Y
MAX dimerization protein 3

of which were distinct from those found using vehicle stimulation [49].
Many of these sites overlap with previously identiﬁed ER binding
regions, and, in accordance with accumulating genomic analysis indicating that the majority of ER binding sites are located in regions far
upstream of the TSS, only a minority (~3%) of E2-dependent p/CIP binding is suggested to occur within 500 bp of the TSS. The level of CARM1
activity (as assayed by its methylation of H3R17 and/or p/CIP) across
the genome also appears to cluster predominantly at a distance from
promoters [50]. These observations of a limited set of proximal promoter
binding sites for p/CIP, and minimal CARM1 methylation activity at
promoter elements correspond with the relatively small number of
promoters we identiﬁed as interacting with the p/CIP/CARM1 complex,

and is also consistent with proximal ER binding events previously identiﬁed using the 1 kb promoter-speciﬁc ChIP-DSL approach [43].
Although now largely superseded by ChiP-Seq, ChIP-DSL is a highly
sensitive assay which eliminates some of the biases introduced by
more conventional ChIP-on-chip whole-genome approaches. In ChIPDSL, the immunoprecipitated genomic DNA is used only as a template
to mediate annealing and ligation of aligned oligonucleotide pairs.
After annealing, the biotinylated DNA is then selected using streptavidin
Sepharose and Taq ligase is used to ligate oligonucleotides positioned
directly adjacent to each other, creating complete amplicons which are
hybridized to a 20,000 gene promoter array. A limitation of this
approach is that analysis is restricted to those promoters found on the
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Fig. 4. p/CIP/CARM1 target genes are directly regulated by E2. (A) Differentially expressed genes after E2-stimulation relative to unstimulated control cells. (B) Realtime RT-PCR
analysis of pS2, Jak2, and Mapk4 following stimulation of MCF-7 cells with 17β-estradiol for 1 h, 3 h, 12 h, and 24 h. Data is expressed as means and standard error of the mean
from repeated experiments, performed independently (pS2 n = 7, Jak2 n= 7, Mapk4 n = 3). Paired student's t-test was performed and statistically signiﬁcant changes from
untreated samples are indicated. (C) Canonical pathway diagram, highlighting statistically signiﬁcant p/CIP/CARM1 complex direct targets in color. Targets in gray are bound by
p/CIP/CARM1 but do not meet statistical criteria. (D) Western blot showing JAK2 levels in MCF7 cells following 17β-estradiol stimulation of MCF7 cells for 1, 3, 12, 24, 48, and
72 h. Relative abundance of protein levels at 12, 24, 48, and 72 h time points was quantiﬁed by densitometry.

array which contain 1 kb of upstream regulatory sequence. Studies have
shown that the majority of ER binding sites are found more distal than
the proximal promoter. Nevertheless, promoter proximal interactions
do occur in response to E2 and this interaction can have transcriptional
consequences. Furthermore, our study does not examine ER binding
directly, but rather focuses on occupancy of p/CIP/CARM1 in response
to E2. Thus, it would theoretically include those targets that are targeted
to promoter regions by E2 independent of direct DNA binding, and
possibly via enhancer–promoter interactions.
A major advantage of this approach is that we identiﬁed 204
promoter-proximal interaction sites for the p/CIP/CARM1 complex,
eliminating the complicated process of assigning responsive genes to
distant binding sites, and instead were able to directly correlate complex
interaction with transcriptional effect. Previous microarray studies with
E2-stimulation can be broadly categorized based on the length of
hormone treatment. There is an observable difference in the pattern of
expression change, such that at early time points (b 6 h) more genes
are upregulated and more variation is evident between time points,
while at later time points (>12 h) there is a more stable pattern of
expression change and the majority of genes are downregulated
[33,44]. We showed that after 12 h of stimulation with E2, 20% of
p/CIP/CARM1 complex target genes identiﬁed by ChIP-DSL were transcriptionally altered (16.2% upregulated and 3.9% downregulated). The

relatively small number of transcriptionally changed target genes after
12 h implies that proximal recruitment of the p/CIP/CARM1 complex
is not predictive of E2-dependent gene expression at this late time
point. However, among those targets that are transcriptionally altered,
the complex plays a preferential role in activation, consistent with the
role of p/CIP as a coactivator. While the changes in target gene expression that we observed were modest, we do observe notable changes in
chromatin modiﬁcations, suggesting that E2 may facilitate crosstalk.
Direct comparison of target gene promoters in our study with
known genomic ER binding sites in MCF-7 cells [under equivalent E2stimulation conditions] [33,34] identiﬁed 59/204 (29%) p/CIP/CARM1
complex targets as putative high-conﬁdence ER binding targets. Therefore, it seems likely that the p/CIP/CARM1 complex is recruited to this
subset of E2-responsive promoters via the ER. We also identiﬁed a
trend in which binding motifs for transcription factors known to facilitate ER recruitment were enriched among p/CIP/CARM1 complex target
promoter sequences. While Sp1, C/EBP, Oct, FoxA1, and AP-1 motifs
have previously been shown to be enriched, in addition to EREs, in the
sequences surrounding ER binding events on a genome-wide scale
[33,42,50], there has not previously been much discussion related to
the proximal promoter region or when considering recruitment of an
E2-regulated complex. Neither the predicted ER-binding state nor the
transcriptional status of complex target genes after 12 h E2 treatment
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Table 2
Genes directly regulated by the p/CIP/CARM1 complexa.
Gene ID

Accession
number

Genes activated by E2
NFKB1
NM_003998
MOCOS
NM_017947
JAK2
NM_004972
STARD4
NM_139164
HARS
NM_002109
IGSF4/
NM_014333
CADM1
KCTD3
NM_016121
GTF2E2
NM_002095
ZIM3
PDCD8
WBP11
PRKRIR

NM_052882
NM_004208
NM_016312
NM_004705

ZNF567
IVNS1ABP
BMI1
M6PR
HSD17B12
TM4SF8
CCNA2
LAP3
POLR2F
RAD9B
DYRK1A

NM_152603
NM_006469
NM_005180
NM_002355
NM_016142
NM_005724
NM_001237
NM_015907
NM_021974
NM_152442
NM_101395

PCNA
PCP4
ZNF800
PELO
DPH2L2
RFXAP
CLDN12
PIAS2
ELAC1
RDH10

NM_002592
NM_006198
NM_176814
NM_015946
NM_001384
NM_000538
NM_012129
NM_004671
NM_018696
NM_172037

Genes repressed by E2
PXMP4
NM_007238
HBD
NM_000519
MAPK4
NM_002747
ITPKB
NM_002221
MXD3
NM_031300
MGC15882 NM_032884
LMOD1
NM_012134
CD9
NM_001769

Description

Nuclear factor of kappa light polypeptide gene enhancer
Enzyme
Janus kinase 2 (a protein tyrosine kinase)
StAR-related lipid transfer (START) domain containing 4
Histidyl-tRNA synthetase
Cell adhesion molecule 1/tumor suppressor
Potassium channel tetramerization domain containing 3
General transcription factor IIE, polypeptide 2, beta
34 kDa
Zinc ﬁnger, imprinted 3/transcription factor
Enzyme/cell death
WW domain binding protein 11
Protein-kinase, interferon-inducible RNA dependent
inhibitor
Transcription factor
Inﬂuenza virus NS1A binding protein
BMI1 polycomb ring ﬁnger oncogene
Mannose-6-phosphate receptor (cation dependent)
Hydroxysteroid (17-beta) dehydrogenase 12
Tetraspanin 3
Cyclin A2/cell cycle
Peptidase
Polymerase (RNA) II (DNA directed) polypeptide F
RAD9 homolog B (S. cerevisiae)/DNA replication
Dual-speciﬁcity tyrosine(Y)-phosphorylation
regulated kinase 1A
Proliferating cell nuclear antigen
Purkinje cell protein 4
Unknown
Pelota homolog (Drosophila)
DPH2 homolog (S. cerevisiae)
Regulatory factor X-associated protein
Calcium-independent cell–cell adhesion
Protein inhibitor of activated STAT, 2
ElaC homolog 1 (E. coli)/trna processing
Retinol dehydrogenase 10 (all-trans)

Peroxisomal membrane protein 4, 24 kDa
Hemoglobin, beta///hemoglobin, delta
Mitogen-activated protein kinase 4
Inositol 1,4,5-trisphosphate 3-kinase B
MAX dimerization protein 3
C1orf94
Leiomodin 1 (smooth muscle)
CD9 molecule/cell adhesion

a
Comparative analysis of ChIP–chip data and expression analysis following 12 h
E2-stimulation of MCF-7 cells allowed for the identiﬁcation of p/CIP/CARM1 regulated
genes.

was predictive of enrichment of transcription factor binding motifs
studied, and so, consensus mechanisms for differential transcriptional
responses as implied by the recruitment of the ER could not be inferred.
Several of the targets identiﬁed are components of the canonical
JAK/STAT signaling pathway. This pathway mediates the activity of a
wide variety of cytokines and growth factors [51]. JAK2 is a central
component of the pathway and is responsible for phosphorylation
and activation of the STAT family of proteins, which normally reside
in the cytoplasm and, upon activation, translocate to the nucleus and
bind to speciﬁc target genes involved in cell proliferation and survival
[51]. JAK2 or STAT5 null mice display phenotypes remarkably similar to the ERα and p/CIP knockout animals including defects in
mammary gland cell proliferation and apoptosis [52,53]. Importantly,
overexpression or constitutive activation of STAT3 and 5 proteins has
been described in many types of cancers [54] and promote the occurrence of sporadic mammary cancers in mice [45,55–57]. In proliferating
ER-positive tumor cells, E2 is known to stimulate phosphorylation and
activation of STAT3 and 5, although the mechanism has not been fully

elucidated [58–60]. The PIAS family, most notably recognized for their
role as coregulators for STAT proteins, is also of interest as PIAS1 has
been shown to sumoylate p/CIP [and other SRCs], affecting activity
and stability in steroid-receptor signaling pathways in MCF7 cells [20].
Collectively, these ﬁndings suggest that ER signaling and the JAK/STAT
pathway may cooperate in the regulation of mechanisms implicated
in mammary cancers. This cooperation may be mediated, at least in
part, through the p/CIP/CARM1 complex.
We observed recruitment of the p/CIP/CARM1 complex to the 1 kb
promoter of Jak2 in response to E2, with a transcriptional upregulation
after 12 and 24 h, but no signiﬁcant effect on protein levels with E2
stimulation. Analysis of histone modiﬁcations to the proximal 1 kb promoter revealed an unclear pattern that was predictive neither of transcriptional activation nor repression. A modest increase in acetylation
of histone H3 at K9 and K14 at a region approximately 1 kb upstream
of the Jak2 TSS in response to E2, which coincides with p/CIP/CARM1
complex recruitment, suggestive of a transcriptionally active gene. In
contrast, there was a lack of discernible change in H3K4me3 in response
to E2 at the same promoter region, a modiﬁcation that would be
expected to be present near the TSS of an actively transcribed gene
[61,62]. We suggest that these changes reﬂect a promoter that is not
necessarily in line with a fully transcriptionally active state but may
instead be permissive, poised for more robust transcriptional activation, in a process that may require additional signals.
Our study of chromatin modiﬁcations was focused to a single time
point for E2 treatment. This is based on previous studies showing maximal p/CIP/CARM1 recruitment to the pS2 promoter 45 min after the
addition of hormone [16]. Importantly, a statistically signiﬁcant E2dependent increase in H3R17me2 was evident, corresponding with
the region of p/CIP/CARM1 recruitment, suggesting the complex is
functional on the Jak2 promoter. Reinforcing this idea, we noted that
following depletion of p/CIP, E2-dependent H3R17me2 of the Jak2
promoter was greatly reduced in addition to an observable loss of
p/CIP recruitment. Finally, siRNA mediated depletion of p/CIP resulted
in a reduction in E2-induced transcription of Jak2, with residual E2responsiveness likely due to functional redundancy between SRC family
members. However, depletion of CARM1 caused a more dramatic loss in
E2-dependent Jak2 transcription, suggesting that its enzymatic activity
is in fact important for the observed regulation by the p/CIP/CARM1
complex. CARM1 activity has previously been associated with the regulation of a subset of the ER cistrome [50], and herein we provide a
speciﬁc example of its E2-dependent recruitment, as part of an active
coregulatory complex, to the Jak2 promoter. We also observed an
increase in phosphorylated STAT3, indicative of activation of the JAK/
STAT signaling pathway. While this activation is not necessarily dependent on Jak2 transcriptional upregulation, this effect was lost following
siRNA-mediated silencing of p/CIP or CARM1.
Collectively, while the changes in E2-dependent H3R17 dimethylation
are indicative of active Jak2 transcription, the other chromatin marks
we examined, as well as the modest response at the RNA and protein
levels, were inconsistent with a fully transcriptionally active promoter. We suggest that an additional signal may be required for a
more robust transcriptional response of the Jak2 gene. In addition,
despite the changes in expression of select genes, the majority of
complex targets did not exhibit a widespread transcriptional response to 12 h E2 treatment, ultimately suggesting that E2 may
cause a general “rewiring” of speciﬁc signaling pathways, through
recruitment of the p/CIP/CARM1 complex, so that many essential
genes become “poised” for transcription.
4. Materials and methods
4.1. Plasmids, antibodies, and reagents
A complete list of primers used can be found in Table A3 of the
supplemental material. Antibodies used in this study are listed in
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Fig. 5. Functional classiﬁcation of p/CIP/CARM1 target gene promoters. (A) Schematic Ingenuity Pathway Analysis indicates (A) that cancer is one of the diseases most commonly
associated with the p/CIP/CARM1 target genes and (B) that molecular and cellular functions associated with the gene set highlight cellular growth and proliferation as
predominating.
Adapted from © 2000–2011 Ingenuity Systems, Inc. All rights reserved.

Table A4 of the supplemental material. All of the antibodies used for
these studies are commercial antibodies, with the exception of the
p/CIP antibody. The method by which this antibody was generated,
puriﬁed, and tested has been previously described [4]. 17β-Estradiol
(water soluble) was purchased from Wisent. All siRNA used was purchased from Dharmacon.
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4.2. Western blotting
Cells were grown in phenol red-free, charcoal stripped DMEM and
stimulated with 10−7 M E2 for various time periods as indicated. Cells
were washed twice in phosphate buffered saline (PBS), harvested and
lysed in RIPA lysis buffer (~150 μl/60 mm plate) consisting of 50 mM
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Fig. 6. Characterizing E2-dependent histone modiﬁcations to Jak2 proximal promoter. (A) Schematic representation of the Jak2 1 kb proximal promoter, highlighting region used
for ChIP analysis. (B) Control and 17β-estradiol stimulated MCF-7 cells were cross-linked with 1% formaldehyde, and ChIP or sequential ChIP–reChIP was performed using the
indicated antibodies, followed by qPCR. ChIPs were performed in triplicate, normalized to IgG, and shown as percentage of Input. Statistical signiﬁcance was determined using
Student's t-test and is indicated by * (p b 0.05). (C–D) ChIP-qPCR analysis of Jak2 promoter following E2 treatment. ChIPs were performed in duplicate (H3K9/k14ac, H3K4me3)
or triplicate (H3R17me2) using indicated antibodies, quantitated with real-time PCR, normalized to IgG control and shown as percentage of Input. Statistical signiﬁcance was
determined using Student's t-test and is indicated by * (p b 0.05).
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Fig. 7. p/CIP/CARM1 mediated E2-dependent regulation of Jak2. (A) Representative Western blot showing 72 h siRNA depletion of p/CIP in MCF7 cells. (B) ChIPs were performed in
triplicate at Jak2 promoter regions using indicated antibodies, quantitated by real-time PCR, normalized to IgG control and shown as a percentage of Input. Data is expressed as
means and standard error of the mean from triplicate experiments. (C–D) Analysis of E2-dependent Jak2 transcription (top) and STAT3 activation (bottom) with siRNAmediated depletion of (C) p/CIP or (D) CARM1. (Top) Realtime RT-PCR analysis of Jak2 was performed following 12 and 24 h exposure to hormone, and data is expressed as the
mean and standard error of the mean from triplicate experiments, performed independently. Student's t-test was used to compare E2-induced expression changes and statistically
signiﬁcant differences from control samples are indicated. (Bottom) Representative Western blot showing knockdown efﬁciency and STAT3 activation in MCF7 cells following E2
treatment.

Tris (pH 8.0), 150 mM NaCl, and 1% NP-40, 0.1% SDS and protease
inhibitor cocktail. Extracts were centrifuged for 10 min at 14,000 rpm
at 4 °C and the soluble fractions were retained. Samples were normalized for protein content and were separated by SDS-PAGE, transferred to nitrocellulose or PVDF membrane and blocked overnight in
PBS containing 0.1% TWEEN-20 and 5% nonfat dried milk. The appropriate antibodies were then diluted in blocking buffer and the membrane was probed for 2 h at room temperature with rocking,
followed by incubation with secondary antibody for 1 h. Proteins
were detected using ECL according to the manufacturer's recommendations (Amersham).

hexamers to generate cDNA. All amplicons were detected using the 5′
nuclease (Taqman) assay with 5′ labeled probes. Probes were already
predesigned and quality tested (Applied Biosystems). Reactions were
performed according to the manufacturer's recommendations (Applied
Biosystems) and were run in replicates of two, in a 96-well format. Each
reaction included 18S RNA as a control for normalization, and reactions
lacking cDNA served as negative controls. Two independent experiments were performed for each gene following treatment with E2,
and a mean value was obtained and compared to the mean expression
level of each gene from untreated cells. Applied Biosystems 7500 Real
Time PCR System software was used to identify cycle threshold (Ct)
for each reaction.

4.3. RNA isolation and real-time PCR
4.4. RNA microarray analysis
Total cellular RNA was isolated using RNeasy kit (Qiagen). The
quality and quantity of RNA were evaluated by measuring OD 260/
280. For real-time PCR analysis, 0.2 μg of RNA was reverse-transcribed
with TaqMan reverse transcriptase (Applied Biosystems) using random

Total RNA was extracted from MCF-7 cells treated with 10 nM E2
for 12 h and from control, untreated cells. Independent biological
triplicates were performed for each treatment, including control
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samples. cDNA was prepared from control and treated samples, labeled
and hybridized to HgU133A + 2 human affymetrix DNA microarray.
Hybridization, washing, scanning and analysis of genechips were
performed at the University of Western Ontario, London Regional
Genomics Centre (London, Ontario, Canada).
An average intensity of each E2-treated sample was compared to the
average intensity for control non-treated samples. Three biological replicates for each array were processed and the data was transformed
using Robust Multi-Array normalization (5) and values below 0.01
were set to 0.01. Each measurement was normalized by dividing all
measurements in that sample by the 50th percentile. Ratios were then
calculated for all samples against the median of the control samples. A
student t-test statistical analysis was conducted and false positives
were reduced using Benjamini and Hochberg false discovery rate.
4.5. Chromatin immunoprecipitation assay
MCF-7 cells were cross-linked with 1% formaldehyde at room
temperature for 5 min. Cross-linking was quenched by immediately
washing cells twice with ice-cold PBS and harvesting in PBS containing
PMSF. Cell pellets were lysed in 0.2 ml of cell lysis buffer (50 mM Tris–
HCl [pH 8.1], 10 mM EDTA, 1% SDS, and protease inhibitors) and incubated on ice for 10 min. Lysates were sonicated to yield DNA fragments
ranging in size from 300- to 1000-bp. Approximately 450 μg of the
cross-linked, sheared chromatin solution was used for immunoprecipitation. A small portion of each IP was saved as input DNA (5%). Supernatants were diluted 10-fold in dilution buffer (20 mM Tris–HCl [pH 8.1],
1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and protease inhibitors)
and immunoprecipitated using a protein A-Sepharose slurry or with
MagnaChIP Protein A magnetic beads.
When using the Protein A-Sepharose slurry, lysates were precleared
with 50 μl of 50% slurry protein A-Sepharose containing 2.5 μg of
sheared salmon sperm DNA for 2 h at 4 °C. Immunoprecipitation was
performed overnight at 4 °C with 1.5–4 μg of the antibodies. 50 μl of
protein A-Sepharose containing 2.5 μg of salmon sperm DNA per ml
was added to the solution and incubated for 1 h at 4 °C. Magnetic
beads were washed using PBS with 0.1% Tween-20, incubated with
the relevant antibodies for 2.5 h at 4 °C, and rewashed prior to immunoprecipitation overnight at 4 °C. The beads were washed one time
each with wash buffer I (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris–HCl, 150 mM NaCl), wash buffer II (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris–HCl, 500 mM NaCl), wash buffer III
(0.25 M LiCl; 1% NP-40; 1% Na-Deoxycholate; 1 mM EDTA; 10 mM
TrisHCl) and twice with TE buffer. Immunoprecipitated material
was extracted twice with 150 μl elution buffer (1% SDS-0.1 M
NaHCO3). If sequential ChIP was conducted, eluted samples were reimmunoprecipitated overnight at 4 °C with 1.5–4 μg of secondary antibodies. Washes and elution steps were repeated. NaCl was added to the
ﬁnal 150 μl eluate to a concentration of 200 mM and the cross-linking
was reversed by heating at 65 °C overnight. DNA was puriﬁed using
Qiagen PCR puriﬁcation spin columns.
For analysis by conventional PCR, conditions were as follows: initial
denaturing cycle of at 94 °C for 3 min, followed by 40 cycles of 94 °C for
30 s, ~57 °C for 30 s and 72 °C for 45 s, and a ﬁnal elongation step of
72 °C for 10 min. For experiments involving E2-stimulation, MCF-7
cells were plated to approximately 90% conﬂuence and treated with
10−7 M E2 for 45 min prior to ChIP analysis.
For some experiments, DNA isolated from ChIP experiments was
subjected to quantitation by real time PCR using Brilliant SYBR
green master mix (Stratagene; 600548). Primers were identiﬁed
using the Primer Express program (Stratagene) and tested to establish
optimum reaction conditions. Reactions were performed in a 25 μl
volume according to manufacturer's recommendations. The reaction
was carried out and measured using Mx3000P realtime instrument.
Standard curves were generated using total input DNA (copy number
range: 8 × 10 5 to 8 × 10 1). The IP and IgG DNA copy number was
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calculated by extrapolating their respective Ct value from the standard
curve. The nonimmune IgG copy number was subtracted from IP DNA
copy number. The resulting IP copy number was initially normalized
against the total input DNA by dividing the IP by input. The average
copy number with E2-treated IPs was then normalized to untreated
control IPs, and recruitment represented as a fold-change with E2treatment. All measurements were done in duplicate and an average
Ct value was used to calculate copy number. Two independent realtime
reactions were done for each experiment.
4.6. ChIP-DSL assay
Chromatin immunoprecipitation coupled to DNA selection and
Ligation (ChIP-DSL) was used to assess global promoter occupancy
by p/CIP/CARM1. MCF-7 cells were cross-linked with formaldehyde
and subjected to standard sequential ChIP–reChIP assay using afﬁnity
puriﬁed anti-p/CIP and anti-CARM1 antibodies. The procedure for
oligonucleotide annealing, solid phase selection ligation and PCR
ampliﬁcation were performed exactly as described (Aviva Systems
Biology; H20K, Cat# AK-0504). The antibody-enriched DNA and the
total input were biotinylated followed by annealing to the 40mer
oligonucleotide pool. The DNA–oligonucleotide complexes are then
selected by binding to streptavidin-conjugated magnetic beads, while
the non-annealed oligonucleotides are washed away. Correctly paired
40mers are then ligated to form the corresponding 80mer which is
ﬂanked by both universal primer annealing sites (T3 and T7) giving
rise to a complete amplicon. A PCR reaction was then conducted on
the amplicons using ﬂuorescently labeled T7 and regular T3 primers.
Total input DNA was PCR ampliﬁed using Cy5 (green) labeled T7 primer
and the immunoprecipitated (IP) sample was ampliﬁed using Cy3 (red)
labeled T7 primer. The PCR products are co-hybridized to the 40mer
array (Hu20K) to derive an enrichment ratio for each target. After
hybridization and washing, array slides were scanned on a One Virtek
(Bio-Rad) Chip Reader, and the ArrayVision (v6.0) software package
(London Regional Genomics Centre, London, Ontario, Canada) was
used to quantify ﬂuorescence intensity. The Chip on chip intensity
values were normalized using a Lowess curve, which was ﬁt to the log
intensity versus log-ratio plot and 20% of the data was used to calculate
the Lowess ﬁt at each point. Following normalization, a two-sided
student's t-test was conducted where standard deviation of the replicates was used to calculate a p-value. Fold change was calculated for
each gene using a mean value that was calculated from all three biological replicates.
4.7. Ingenuity Pathway Analysis
Ingenuity Pathways Systems (http://www.ingenuity.com) analysis
was employed to group statistically signiﬁcant genes. The 204 genes
that bound p/CIP/CARM1 directly and were transcriptionally affected
by E2 were considered for Functional Analysis to identify the biological
functions and/or diseases that were most signiﬁcant to the data set. A
right‐tailed Fisher's exact test was used to calculate a p‐value determining the probability that each biological function and/or disease assigned
to that data set is due to chance alone.
4.8. Promoter enrichment analysis
Promoter sequences were identiﬁed using Gene2Promoter within
the Genomatix Suite (www.genomatix.de). Input was in the form of
gene accession numbers, and comparison with transcripts that have
been mapped to the ElDorado genome yielded mapped sequence
results and extracted promoters. A deﬁned 1000 bp upstream of the
mapped transcriptional start sites were selected for further transcription factor binding site analysis. To search for enriched consenus motifs
within ElDorado extracted promoter sequences the BIOBASE Knowledge Library was used, making use of MATCH software and the Transfac
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database. Searches were performed with the best supported promoters
using the vertebrate non redundant (minFP) proﬁle. Background
frequencies were determined using control set of human housekeeping
gene promoters. Optimized matrix cutoffs and search window positions
were used. Signiﬁcant matrices were found with p-valueb 0.001 and
Yes/No>1.2.
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